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Abstract
Background: Sepsis research relies on animal models to investigate the mechanisms
of the dysregulated host response to infection. Animal welfare concerns request the
use of potent analgesics for the Refinement of existing sepsis models, according to
the 3Rs principle. Nevertheless, adequate analgesia is often missing, partly because
the effects of analgesics in this particular condition are unknown. We evaluated the
use of nalbuphine, an opioid with kappa agonistic and mu antagonistic effects, in
rats with and without experimental sepsis.
Methods: Male Wistar rats were anesthetized with isoflurane and instrumented with
a venous line for drug administration. Arterial cannulation allowed for blood pressure
measurements and blood sampling in short-term experiments of non-septic animals.
Nalbuphine (or placebo) was administered intravenously at a dose of 1 mg/kg/h.
Long-term (48 h) experiments in awake septic animals included repetitive clinical
scoring with the Rat Grimace Scale and continuous heart rate monitoring by
telemetry. Sepsis was induced by intraperitoneal injection of faecal slurry. Nalbuphine
plasma levels were measured by liquid chromatography—high resolution mass
spectrometry.
Results: In anesthetized healthy animals, nalbuphine led to a significant reduction of
respiratory rate, heart rate, and mean arterial pressure during short-term experiments. In
awake septic animals, a continuous nalbuphine infusion did not affect heart rate but
significantly improved the values of the Rat Grimace Scale. Nalbuphine plasma
concentrations remained stable between 4 and 24 h of continuous infusion in septic rats.
Conclusions: In anaesthetised rats, nalbuphine depresses respiratory rate, heart rate,
and blood pressure. In awake animals, nalbuphine analgesia improves animal
welfare during sepsis.
Keywords: Animal welfare, Analgesia, Nalbuphine, Sepsis, Rat model, Faecal peritonitis, 3R
Background
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host
response to infection [1, 2]. Due to the complexity of the illness, current sepsis
research relies on animal models to investigate underlying mechanisms and novel
therapeutic options [3].
Intensive Care Medicine
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Faecal peritonitis in rats is a widely used animal model in sepsis research [4–7]. To date,
this animal model has mostly been performed without adequate analgesia, although faecal
peritonitis may cause considerable suffering [8]. Animal welfare strongly requests ad-
equate analgesia for research animals [9]. Nevertheless, adequate analgesia is often miss-
ing, partly because treatment recommendations are missing, partly because the effects of
analgesics in this particular condition are unknown [3]. Evidence for appropriate analgesia
in septic animals is scarce and guidelines are missing. We recently reviewed different anal-
gesic regimens in sepsis models [10].
Nalbuphine is an opioid analgesic and acts as a kappa agonist and mu-receptor antag-
onist. An advantage of nalbuphine is its ceiling effect compared to pure mu agonists like
morphine or fentanyl [11]. Therefore, side effects such as respiratory depression or gastro-
intestinal complications are less common [12, 13]. In addition, nalbuphine is not a con-
trolled substance by the law on narcotics (in contrast to buprenorphine or morphine),
which facilitates its use in laboratory animals. Compared to morphine, the analgesic
potential of nalbuphine has been estimated to be at 0.8–0.9 [14].
Objectives
Aims of this placebo-controlled study were (a) to test the short-term respiratory and car-
diovascular effects of nalbuphine in anesthetized non-septic animals, (b) to investigate the
behavioural and cardiovascular effects of nalbuphine in awake rats with faecal peritonitis
over 48 h (compared to non-septic animals and placebo), and (c) to measure nalbuphine
plasma concentrations during early and established sepsis.
Methods
Setting
All animal experiments were performed in the animal laboratories at the University
Hospital Zurich, Switzerland. The animal model has been adapted from an established
model of faecal peritonitis by the modification of fluid resuscitation and the addition of
antibiotic therapy and analgesia [4, 15].
Ethical considerations
All experimental protocols were approved by the local veterinary office (Kanton of Zurich,
Switzerland, applications 95/2012 and 163/2014). Experiments are graded as class I
(European category: “non-recovery”) for short-term experiments, class II (European cat-
egory: “moderate”) for long-term experiments in non-septic control animals and class III
(European category: “severe”) for long-term experiments in septic animals [16]. Principles
of the 3Rs were implemented, and humane endpoints were applied as described below.
Research animals
Male Wistar rats (mean weight 416 ± 76 grams, n = 45 were housed in groups of three to
four animals in the local animal unit for at least 5 days prior to the experiments, with free
access to food and water, a card board tube and autoclaved hay as nest material. During
experiments, animals were single-housed.
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Study design
Randomized, placebo controlled animal model. Animals were either randomized to
short-term (30 min) placebo (n = 6) and short-term nalbuphine (n = 6) or randomized
to long-term (48 h) sham or sepsis, with or without nalbuphine (n = 23). Figure 1 sum-
marises the animal numbers per group and Figs. 2 and 3 display the study design for
the short- and long-term experiments.
Nalbuphine
The content of one vial of nalbuphine (20 mg/2 ml; OrPha Swiss GmbH, Kuesnacht,
Switzerland) was diluted in 18 ml of NaCl 0.9%, to obtain a solution with 1 mg/ml. The
dose for this study was established in pilot experiments (n = 4): One septic animal bene-
fited from a dose increment from 0.5 to 1 mg/kg/h iv, which reduced clinical pain accord-
ing to the Rat Grimace Scale. However, no benefits were noted when the nalbuphine dose
was further increased. Hence, the dose of 1 mg/kg/h was used in subsequent experiments.
Experimental protocols
Short-term experiments (30 min)
General anaesthesia was induced by isoflurane, which was administered to the spontan-
eously breathing animals at a dose of 2.5% in room air (gas flow 400 ml/min). Lidocaine 1%
(local pharmacy, University Hospital Zurich, Switzerland) was used at a dose of 2 ml/kg for
local anaesthesia. After surgical exposure, PVC tubes (ID 0.58 mm, OD 0.96 mm; Smiths
Medical Int, Kent, UK) were inserted into the right jugular vein and the right carotid artery.
The fluid filled arterial line was attached to a pressure transducer (ADInstruments, Oxford,
UK), which allowed blood pressure measurements and sampling of arterial blood. The
transducer was connected via a bridge amplifier (ML 221, ADInstruments, Oxford, UK) to
a recorder (Power Lab 4/30, ML 866, ADInstruments, Oxford, UK) and a computer. Blood
pressure, heart rate, and respiration rate were recorded and analysed with specialised
Fig. 1 Randomization of animals to experimental groups. Animals were randomized within the short term
and within the long term group. Grey background: groups receiving nalbuphine; bold font: septic groups.
Asterisk (*): nalbuphine concentration at 15 min measured in plasma samples from short-term group
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software (LabChart Pro 7 for Windows, ADInstruments, Oxford, UK). Blood gas analysis
was performed with an Epoc blood analysis system (Epocal Inc. Ottawa, ON, Canada).
Twelve healthy animals were randomized to nalbuphine or placebo without induction
of sepsis. Animals in the nalbuphine group received 2 mg/kg nalbuphine subcutaneously
for analgesia after anaesthesia induction, but prior to instrumentation, the subcutaneous
administration of nalbuphine in combination with lidocaine was requested by the animal
ethics committee in order to avoid post-operative pain after termination of isoflurane an-
aesthesia. Placebo animals received a subcutaneous injection of normal saline (2 ml/kg).
After instrumentation, a nalbuphine infusion was started at a dose of 1 mg/kg/h. After
15 min, the dose was increased to 5 mg/kg/h for another 15 min. After each phase, blood
sampling and hemodynamic monitoring was performed (Fig. 1). All animals remained
under isoflurane anaesthesia until they were euthanized by an intravenous injection of
Fig. 2 Design of short-term experiments. Animals were randomized to either nalbuphine or placebo (NaCl 0.9%)
infusions. OP operation (=instrumentation). The subcutaneous administration of nalbuphine in combination with
lidocaine was requested by the animal ethics committee in order to avoid post-operative pain after termination of
isoflurane anaesthesia. Placebo animals received a subcutaneous injection of normal saline (2 ml/kg)
Fig. 3 Design of long-term experiments. Animals underwent either faecal peritonitis or sham (NaCl 0.9%) i.p.
injection and were subsequently randomized to either nalbuphine (1 mg/kg/h) or placebo (NaCl 0.9% 1 ml/kg/h)
infusion. Asterisks indicate frequency of clinical scoring (6, 12, 24, 36, and 48 h). AB: antibiotics (ceftriaxone, 30 mg/
kg i.v.); OP operation (=instrumentation). The subcutaneous administration of nalbuphine in combination with
lidocaine was requested by the animal ethics committee in order to avoid post-operative pain after termination of
isoflurane anaesthesia. Placebo animals received a subcutaneous injection of normal saline (2 ml/kg)
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1 ml phenobarbital (Esconarkon ad us. Vet., Streuli Pharma AG, Uznach, Switzerland) at
the end of the experiment.
Long-term model (48 h)
Under anaesthesia as described above, two electrodes and a telemeter (TR50B, Millar,
Houston, TX, USA) were implanted subcutaneously [17]. Heart rate was recorded con-
tinuously by a wireless data acquisition system (TR180 SmartPad, Millar, Houston, TX,
USA). Heart rate readings were recorded with PowerLab and analysed with LabChart
Pro (see Jeger et al. [10] for picture) by a blinded investigator (M.A.). Delta heart rate
was calculated as heart rate at time point x minus heart rate at baseline.
Subsequently, a PVC tube was inserted into the right jugular vein and tunnelled sub-
cutaneously to emerge at the nape of the neck. This line was subsequently attached to
a swivel-tether system (UNO BV, Zevenaar, the Netherlands) allowing the rat to have
unrestrained movement in its cage and free access to food and water (see Jeger et al.
[10] for picture).
Sepsis was induced by an intraperitoneal injection of faecal slurry (n = 10), which
contained faeces collected from several animals of the same batch, diluted in Ringer’s
acetate (suspension 25%), and then filtered. After sepsis induction, isoflurane anaesthe-
sia was stopped and the animals were transferred into their cages. Sham animals (n =
13) received no intra-peritoneal injection to avoid injury of abdominal organs.
Fluid resuscitation with Ringer’s acetate (Ringerfundin, B. Braun Medical AG, Sempach,
Switzerland) was started four hours after peritonitis induction through the central venous
line. After a fluid bolus of 20 ml/kg given over 15 min, crystalloids were infused at a rate
of 10 ml/kg/h between 4 and 8 h. At 8 h, the infusion rate was reduced to 5 ml/kg/h. At
24 h, the infusion rate was further decreased to 2.5 ml/kg/h (Fig. 3).
Ceftriaxone (Rocephin, Roche Pharma, Reinach, Switzerland) 30 mg/kg was given
intravenously 4 and 24 h after the septic insult [18].
Animals from both groups were randomized to nalbuphine or placebo and observed for
up to 48 h (Fig. 3). Animals in the nalbuphine group received 2 mg/kg nalbuphine (Orpha
Swiss GmbH, Kuesnacht, Switzerland) subcutaneously for analgesia prior to instrumenta-
tion. Placebo animals received a subcutaneous injection of normal saline (2 ml/kg). After
instrumentation, a nalbuphine infusion was started at a dose of 1 mg/kg/h and continued
until the end of experiment. Animals in the placebo group received no post-operative an-
algesia but received a continuous infusion with NaCl 0.9% as vehicle at 1 ml/kg/h.
Pain and disease severity were regularly assessed using the Rat Grimace Scale [19] and a
clinical score including back arching, writhing, twitching, piloerection, and/or bloated ab-
domen (Table 1). The investigators of the clinical score and the Rat Grimace Scale (TH,
PJ) were blinded to the treatment regimen (nalbuphine vs placebo).
Humane endpoints (requested by the animal ethics committee) were reached if 6 or
more points were obtained in the clinical score. Animals were euthanized as described
above when termination criteria were fulfilled or at the end of the experiment after 48 h.
Nalbuphine plasma concentrations
Animals were prepared as described above. Arterial blood was sampled 15 min (n = 6) in
short-term experiments and 4 hours (n = 6) and 24 h (n = 4) after the septic insult. These
plasma samples were obtained for another study, using the same setup (data not shown).
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Nalbuphine was determined in plasma using liquid chromatography—high resolution
mass spectrometry (LC-HRMS). To 150 μl of sample, 75 μl of methanol containing the in-
ternal standard (naltrexone, 50 μg/L) was added. After centrifugation for 10 min at 4 °C
and 11,700×g, 80 μl were directly injected into the turbulent flow online extraction sys-
tem. As mobile phases, 10 mM ammonium acetate in water + 0.1% formic acid and
10 mM ammonium acetate in methanol/acetonitrile 50/50 v/v + 0.1% formic acid were
used. For online extraction, a Cyclone column (50 × 0.5 mm) and for analytical chroma-
tography a Hypersil Gold C8 column (100 × 3mm) were used. The mass spectrometer
was operated in positively heated electrospray ionization mode.
Statistics
All results are indicated as mean ± standard deviation. Normality distribution was as-
sumed but it could not be tested conclusively due to the small sample size of each group.
Independent groups were compared using the unpaired t test, paired data were compared
using the paired t test (short-term experiments). Repeated measures ANOVA were used
to detect time or drug effects on heart rate over time. Missing values were replaced by the
last recorded value (carrying forward) for heart rate and clinical scores. One-way ANOVA
was used to determine differences between more than two groups, followed by post-hoc
tests corrected by the Bonferroni method for multiple comparisons (nalbuphine plasma
concentrations, cumulative clinical scores). Graph-Pad Prism 6 (GraphPad Software, La
Jolla CA, USA) was used to calculate the statistics and to draw the figures.
Results
Short-term experiments (30 min)
During isoflurane anaesthesia, an infusion of nalbuphine at 1 mg/kg/h led to a signifi-
cant reduction of respiratory rate, heart rate and mean arterial pressure (Table 2) com-
pared to the placebo-group. Blood sampling following the higher nalbuphine dose
(5 mg/kg/h) revealed lower arterial oxygen saturation and reduced pH when compared
to the prior blood sampling at 1 mg/kg/h nalbuphine in the same animals.
Long-term experiments (48 h)
All sham animals treated with placebo survived (mortality 0%, Fig. 4). In the non-
septic sham group, two out of eight animals randomized to nalbuphine died (mor-
tality 25%; death at 4 and 8 h after the end of instrumentation). The clinical scores
in the non-septic animals remained low during the entire observation period with
Table 1 Score sheet to assess sepsis-induced behaviour changes
Rat grimace scale Clinical scoring*
Orbital tightening 0□ 1□ 2□ Reduced activity 0□ 1□ 2□
Nose/cheek flattening 0□ 1□ 2□ Sunken flanks 0□ 1□ 2□
Ear changes 0□ 1□ 2□ Back arching 0□ 1□ 2□
Whisker changes 0□ 1□ 2□ Piloerection 0□ 1□ 2□
Bloated abdomen 0□ 1□ 2□
Chromodacryorrhea (= eye discharge) 0□ 1□ 2□
Legend: The score sheet was adapted from [17] and www.ahwla.org.uk. *Six or more points in the clinical scoring lead to
a preterm abortion of the experiment by injection of 1 ml phenobarbital i.v.
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and without nalbuphine (Fig. 5). There was no significant difference in the Rat
Grimace Scale and the clinical score at 24 and 48 h between the sham placebo
and sham nalbuphine groups.
In the sepsis group, three out of five animals randomized to nalbuphine died (mortal-
ity 60%; one shortly after peritonitis induction, one each at 8 and 21 h, Fig. 4). No sep-
tic animal in the nalbuphine group fulfilled the predefined termination criteria. In the
septic animals randomized to placebo, two out of five died (one each at 11 and 21 h).
However, two out of the three remaining animals from this group had to be prema-
turely euthanized at 5 and 22 h due to the high clinical scoring (>6 points) as requested
by the animal ethics committee. When the cumulative scores after 24 h were compared,
nalbuphine could decrease the Rat Grimace Scale at 24 h, whereas the clinical score
was not significantly different (Fig. 5).
Fig. 4 Survival curve of long-term experiments (48 h). Survival of long term experiments (48-h observation).
Arrows indicate termination of experiments in the sepsis placebo group due to high clinical scoring
Fig. 5 Rat Grimace Scale and clinical scoring over time. Individual scores are displayed over time. To
determine the effect of nalbuphine on behaviour in sham and septic rats, cumulative scores of each animal
were compared by ANOVA followed by post-hoc tests. In septic animals, nalbuphine significantly reduced
the scores of the Rat Grimace Scale at 24 h (9 ± 2 vs 5 ± 3, p < 0.043), but not the clinical scores at 24 h (12
± 3 vs 9 ± 2, p = 0.190). Due to mortality and premature termination of experiments, cumulative scores were
not compared at 48 h in septic animals. In sham animals, there was no difference in cumulative scores at
24 and 48 h with and without nalbuphine. Data is shown as mean ± standard deviation
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Baseline heart rate for sham and septic animals were 394 ± 49 and 365 ± 50 bpm, re-
spectively. Changes in heart rate are shown in Fig. 6. In sham animals, heart rate de-
creased from 394 ± 49 to 320 ± 44 bpm, p = 0.002 (paired t test) over time. In septic
animals, heart rate increased after sepsis induction and started to decrease after 8 to
10 h. Heart rates were not significantly different between nalbuphine and placebo
within sham or sepsis groups.
Nalbuphine plasma concentrations
Nalbuphine plasma concentration was 22.9 ± 9.0 μg/l after the combination of a s.c.
nalbuphine bolus of 2 mg/kg and an intravenous infusion of 1 mg/kg/h over 15 min.
Plasma concentrations in septic animals after 4 and 24 h of a continuous nalbuphine-
infusion of 1 mg/kg/h were 76.7 ± 24.7 μg/l and 93.0 ± 26.2 μg/l, respectively, and sig-
nificantly higher compared to blood samples drawn after 15 min (Fig. 7). However,
there was no significant difference between 4 and 24 h.
Discussion
The main findings of this study were that (a) nalbuphine led to a reduction of respira-
tory rate, heart rate and mean arterial pressure during general anaesthesia with isoflur-
ane; (b) a fivefold increase of the nalbuphine dose did not worsen these variables
compared to the lower dose; (c) a continuous nalbuphine infusion did not affect the be-
haviour of sham animals; (d) septic animals receiving nalbuphine had lower values in
the Rat Grimace Scale, which could reflect reduced pain and distress perception; (e) in
septic animals, continuous nalbuphine infusion had no influence on heart rate; and (f )
nalbuphine plasma concentrations were stable without accumulation over time.
Analgesia during experimental sepsis is an issue of animal welfare. It corresponds to
the Refinement of the 3R principles [20]. Consequently, legal restrictions and animal
ethics get more and more demanding. In Switzerland, the introduction of the term Ani-
mal’s Dignity in national law requires strict obligations by the local animal committees
[21]. This is even more true for level 3 animal experiments (corresponds to the
European category “severe”) like awake sepsis models as described in the present study.
In awake and therefore spontaneous breathing animal models of sepsis, the use of
pure mu agonists as fentanyl or morphine has major drawbacks like severe respiratory
depression, prolonged gastric emptying and delayed gastrointestinal passage. Therefore,
the use of mixed kappa agonists and mu antagonists like buprenorphine or nalbuphine
Fig. 6 Heart rate changes over time. Delta heart rate was calculated as heart rate at time point x minus heart
rate at baseline. Data are shown as mean ± standard deviation. Repeated measures ANOVA revealed a time
effect for sham and septic animals (p < 0.01, each). There was no group effect or time-group interaction due to
nalbuphine in sham or septic animals
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has advantages [12]. Their ceiling effect reduces the incidence of respiratory depression
and gastrointestinal side effects [13, 22]. In contrast to buprenorphine, nalbuphine is
not regulated by the law on narcotics. It can therefore be ordered and stored without
special restrictions, which facilitates its use in laboratory animals.
Our data on the use of nalbuphine in combination with isoflurane confirmed an earlier
study in which nalbuphine plus cyclopropane induced some degree of respiratory depres-
sion [13]. At similar infusion rates as used in our study, a plateau effect on respiratory de-
pression was observed. Only an infusion rate of 12 mg/kg/h induced a further increase of
arterial PCO2 [13]. If nalbuphine is used in addition to inhalation anaesthesia, we suggest
to increase the oxygen content in the inspiratory gas to avoid hypoxemia. Of note, exces-
sive oxygen supply may be harmful [23]. It has been shown that nalbuphine reduces the
minimal alveolar concentration (MAC) of inhalation anaesthetics which might potentiate
respiratory depression [13]. In our study, animals in the placebo group did not react to
painful stimuli during surgery, nor did they show a higher heart rate. This suggests, that
subcutaneous nalbuphine in addition to lidocaine prior to instrumentation and the con-
tinuous infusions after venous cannulation does not add any benefit to the research ani-
mal, but puts it at risk to hypoxemia and hypercapnia. We therefore suggest to use local
anaesthesia (e.g., lidocaine s.c.) in combination to inhalation anaesthetics and to withhold
nalbuphine until the end of anaesthesia.
We evaluated the analgesic effects using both, clinical scoring and the Rat Grimace
Scale. Recently, it has been shown that the Rat grimace scale could be used in real-time
compared to the standard method of retrospective video-still analysis [24]. In sham ani-
mals, the analysis of cumulative scores revealed no significant effect of nalbuphine on the
behaviour in comparison to placebo. This suggests that intravenous nalbuphine does not
mimic the sepsis phenotype in control animals. However, 2 out of 8 animals in the sham
group treated with nalbuphine died, and the cause therefore remains unclear. Potentially,
hypoxia and/or hypercapnia during instrumentation may have caused the demise of these
animals. In placebo treated animals, an observation over 48 h revealed a low severity in
clinical scores. This supports the notion, that severity of instrumentation and single-cage
housing for 48 h alone can be classified as class II (European category: “moderate”).
Fig. 7 Nalbuphine plasma levels. Nalbuphine plasma levels at 15 min (sham nalbuphine, n= 6), 4 h (sepsis
nalbuphine, n= 6) and 24 h (sepsis nalbuphine, n= 4). Samples were obtained from independent animals without
repeated blood sampling (one-way ANOVA p< 0.001). Post-hoc test revealed significantly higher plasma levels at
4 h (§: p= 0.002) and 24 h (£: p< 0.001) vs 15 min. There was no significant difference between 4 and 24 h
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In septic animals, placebo-treated animals showed signs of severe illness. Two out
of three animals fulfilled the predefined termination criteria and had to be euthanized.
In contrast to the placebo group, septic animals receiving nalbuphine did never reach
the maximum scores, which would have let to termination of the experiment. Overall,
we observed lower values of the Rat Grimace Scale in the nalbuphine group com-
pared to placebo. These effects were obtained without influencing the disease itself as
suggested by the fact that sepsis-induced increase of heart rate was not blunted by
nalbuphine. Therefore, we could reach our main goal of improving animal welfare by
reducing distress in severe animal experiments without detecting heart rate changes
over time. To our knowledge, there are no reports of nalbuphine and its effect on be-
haviour changes in experimental sepsis so far [10]. Further research is needed to im-
plement robust, user-independent items for score-sheets to assess pain and distress in
experimental sepsis.
Regarding plasma concentrations, a continuous intravenous infusion of 1 mg/kg/h nalbu-
phine over 15 min did not reach steady state drug concentrations when compared to the
plasma levels at 4 h. Once a steady state was reached, our results were within the range ob-
served by others [13]. In established sepsis (24 h), we observed stable plasma concentrations
and no further accumulation. Assessment of pain in animals is difficult, even with clinical
scoring systems. Therefore, patient-data may help to correlate plasma-levels with its anti-
analgesic effects. Pugh et al. used a similar infusion rate as in the present study in patients
after abdominal surgery with adequate analgesic action and very comparable plasma-levels
(37–145 μg/L) [25].
Limitations
The limitations of our study are the rather small numbers of animals per group. Our data
are therefore underpowered to exclude that the observed beneficial effect of nalbuphine
on the wellbeing of Wistar rats had an adverse effect on mortality. No repeated blood
sampling was performed in long-term experiments. However, repetitive blood sampling
(e.g., via tail vein under brief sedation) likely would have influenced the outcome during
the 48-h mortality study. Premature termination of experiments affected the outcome. A
clinical score of six had been defined as a humane endpoint by our veterinary committee.
There is however scarce evidence in septic rats that this threshold corresponds to
imminent death. Within the short-term experiments, the order of the low and high nalbu-
phine dose was always the same; therefore, a bias due to the order of the experiment can-
not be excluded. Finally, we cannot provide data on possible immune system changes in
sepsis due to nalbuphine. However, interactions of the immune system with opioids have
mainly been reported for morphine [26, 27]. In CLP mice, buprenorphine or tramadol
had some effects on white blood cells and cytokines [28, 29].
The present study has only been performed in male Wistar rats. However, sex as well
as strain differences have been reported, which should be taken into consideration for
the translation of our results to other setups [10, 30].
Conclusions
If nalbuphine is used during inhalative anaesthesia with isoflurane, laboratory rats are
at risk of hypoventilation with subsequent hypoxemia and hypercapnia. It might be
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advisable to add extra oxygen to the inspiratory gas or, even better, to withhold the
nalbuphine administration until the end of the inhalative anaesthesia.
Further behavioural studies are needed to compare changes in rat models of faecal
peritonitis with CLP models in mice, where more extensive research has already been
done [28]. The behavioural changes and clinical effects due to sepsis in these two spe-
cies are quite different and there are no studies comparing them both in a uniform set-
ting. Especially the correlation of clinical scores with objective parameters (laboratory
parameters or physiological variables) should be evaluated to determine better thresh-
olds for humane endpoints. Furthermore, effects on inflammation/immunomodulation
and organ dysfunction should be included in the assessment of analgesic treatments in
sepsis. As buprenorphine is more widely used than nalbuphine, the direct comparison
of both analgesics could be another focus for upcoming studies. In this context, special
emphasis has to be made for comparisons of continuous iv infusion versus repeated sc
injections. Buprenorphine may be more suitable for repeated sc injections due to its
longer half-life compared to nalbuphine. Our results from continuous infusions can
therefore not be directly translated to repeated sc injections.
In awake experimental sepsis, a continuous infusion of nalbuphine 1 mg/kg/h seems
to provide sufficient analgesia in septic rats without affecting the course of the disease.
Hence, nalbuphine can be recommended in such experiments of high severity as it im-
proves animal welfare.
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